All In Biotech

Drug Trial Radar · NCT06330064

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

A Phase 1B/2 Pan-Tumor, Open-Label Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

680

Planned (sponsor's estimate)

Start

Apr 10, 2024

Primary completion

Jul 25, 2028

Study completion Jul 25, 2028

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Mar 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; cutaneous melanoma; and neuroendocrine carcinoma (NEC).

Conditions

  • Recurrent or Metastatic Solid Tumors

Interventions

  • Ifinatamab deruxtecanDrug

    Intravenous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) as Assessed by InvestigatorTime frame: From the time of the first dose of study drug until the date of documented disease progression, death, loss to follow-up, or withdrawal by the subject, whichever occurs first (up to approximately 60 months)
  2. Number of Participants Reporting Dose-limiting Toxicities (DLTs) in the HCC CohortTime frame: Cycle 1 Day 1 to Cycle 1 Day 21
  3. Number of Participants Reporting TEAEs and Death in the HCC CohortTime frame: From date of signing the informed consent form up to 47 days after the last dose of study drug, up to approximately 60 months

Locations

120 sites in 18 countries. Site status is shown where the registry gives one.

  • Valkyrie Clinical Trials

    Los Angeles, California · Active not recruiting

  • Los Angeles Cancer Network

    Los Angeles, California · Recruiting

  • Pih Health Hematology Medical Oncology

    Whittier, California · Recruiting

  • Orchard Healthcare Research Inc

    Skokie, Illinois · Recruiting

  • M Health Fairview University of Minnesota Medical Center

    Minneapolis, Minnesota · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Icahn School of Medicine At Mount Sinai Prime

    New York, New York · Recruiting

  • Clinical Research Alliance, Inc

    Westbury, New York · Recruiting

  • White Plains Hospital

    White Plains, New York · Recruiting

  • Erlanger Health, Inc

    Chattanooga, Tennessee · Recruiting

  • The West Clinic

    Germantown, Tennessee · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Texas Oncology - West Texas

    Amarillo, Texas · Recruiting

  • Texas Oncology, P.A.

    Dallas, Texas · Recruiting

  • Texas Oncology Gulf Coast

    Pearland, Texas · Recruiting

  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utah · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Wenatchee Valley Hospital and Clinics

    Wenatchee, Washington · Recruiting

  • DIABAID

    Buenos Aires, Argentina · Not yet recruiting

  • Centro Médico Austral

    Ciudad Autonoma Buenos Aires, Argentina · Active not recruiting

  • Centro de Investigaciones Medicas y Desarrollo LC SRL LC Investigacion

    Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • Centro de Investigaciones Medicas Mar Del Plata

    Mar del Plata, Buenos Aires, Argentina · Recruiting

  • Hospital Aleman

    Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • Hospital Sirio Libanes

    Caba, Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • Blacktown Hospital

    Blacktown, New South Wales, Australia · Recruiting

  • St Vincent'S Hospital Sydney

    Mount Kuring-Gai, New South Wales, Australia · Recruiting

  • Genesiscare North Shore Oncology

    St Leonards, New South Wales, Australia · Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia · Recruiting

  • St John of God Subiaco Hospital

    Subiaco, Western Australia, Australia · Recruiting

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium · Recruiting

  • Grand Hospital de Charleroi

    Charleroi, Belgium · Recruiting

  • Universitair Ziekenhuis Gent

    Ghent, Belgium · Not yet recruiting

  • Uz Leuven

    Leuven, Belgium · Recruiting

  • Chu de Liă Ge

    Liège, Belgium · Not yet recruiting

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Hospital São Lucas Da Pucrs

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Cepon - Centro de Pesquisas Oncolă"Gicas de Santa Catarina

    Florianópolis, Santa Catarina, Brazil · Recruiting

  • Hospital de Câncer de Barretos - Fundação Pio XII

    Barretos, São Paulo, Brazil · Recruiting

  • Centro de Pesquisas Clinicas da Fundação Doutor Amaral Carvalho

    Jaú, São Paulo, Brazil · Recruiting

  • Ic La Serena Research

    La Serena, Chile · Not yet recruiting

Showing 40 of 120 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.